Iolyx Therapeutics reports phase 2 results for ILYX-002 in autoimmune-associated dry eye disease

(Image Credit: AdobeStock/Chaosamran_Studio)

Iolyx Therapeutics announced top-line data from its phase 2 trial of ILYX-002 for the treatment moderate-to-severe dry eye disease (DED) associated with systemic autoimmune or inflammatory conditions

The trial is a randomized, double-masked, and vehicle-controlled study conducted at multiple sites across Australia. After a 14-day vehicle run-in period, 105 participants were randomized to receive either ILYX-002 or vehicle control, administered twice daily for 8 weeks, followed by a 2-week safety follow-up.

The trial's primary endpoint was total conjunctival staining, while the secondary endpoint was total corneal staining. According to the company, results showed “a meaningful clinical improvement in ocular surface health,” and a significance for both staining endpoints at day 15. The company noted that this highlighted a rapid onset of action and durable effects through day 57 when compared to a vehicle control.

Mark Hinds, BSc Optom, founder of Ophthalmic Trials Australia, and principal investigator for the ILYX-002-201 phase 2 trial, commented on the results in a press release.

“In this Phase 2 study I observed clinically meaningful, statistically significant improvements on the ocular surface—and what’s remarkable is how fast the effect appeared. A treatment difference of this magnitude in just 2 weeks is something we normally see only with topical steroids, yet we recorded zero discontinuations for tolerability and no IOP concerns. Better still, the benefit was sustained through week 8, confirming a durable response for patients who have had very few safe options.”

Results showed a -1.41-point LS-mean advantage versus vehicle control in total corneal fluorescein staining (tCFS) as early as day 15 (p = 0.0015), increasing to -1.78 points at day 57 (p = 0.0021). This was a 36–44 % improvement from baseline in the active arm versus 15–17% with vehicle control.

The conjunctival endpoint, measured by lissamine green conjunctival staining (tLGCS), showed statistical significance at day 15 with a -1.10-point LS-mean difference (p = 0.0425). At day 57, ILYX-002 maintained a -0.97-point separation (p = 0.0807).

The company noted that treatment-emergent adverse events were “mostly mild to moderate,” with no treatment-related serious adverse events and no discontinuations related to product instillation.

Planning for a phase 3 clinical trial, similar to the phase 2 ILYX-002-201 trial, is ongoing and slated to begin in late 2025.

References:

1. Iolyx Therapeutics announces phase 2 results for ILYX-002 in autoimmune dry eye disease. Published May 27, 2025. Accessed May 27, 2025. https://www.globenewswire.com/news-release/2025/05/27/3088611/0/en/Iolyx-Therapeutics-Announces-Phase-2-Results-for-ILYX-002-in-Autoimmune-Dry-Eye-Disease.html